Vanda Pharmaceuticals rejects Cycle Pharma’s second takeover offer
(Reuters) -Vanda Pharmaceuticals on Monday rejected UK-based Cycle Pharmaceuticals’ second takeover proposal, which values the drugmaker at $8 per share despite a drop in Vanda (NASDAQ:VNDA)’s stock following the FDA’s…